Brokerages Set Geron Co. (NASDAQ:GERN) PT at $7.06

Geron Co. (NASDAQ:GERN) has been given an average rating of “Buy” by the ten analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $6.94.

Several equities research analysts have commented on the stock. Leerink Partners began coverage on shares of Geron in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of Geron in a research report on Friday, August 9th. StockNews.com upgraded shares of Geron to a “sell” rating in a research report on Monday, August 5th. Scotiabank initiated coverage on Geron in a report on Wednesday. They issued a “sector outperform” rating and a $6.00 price target on the stock. Finally, Leerink Partnrs raised Geron to a “strong-buy” rating in a report on Monday, September 9th.

Geron Stock Up 0.7 %

GERN opened at $4.09 on Friday. Geron has a 52 week low of $1.64 and a 52 week high of $5.34. The business has a 50 day moving average price of $4.43 and a two-hundred day moving average price of $4.24. The company has a quick ratio of 3.60, a current ratio of 3.61 and a debt-to-equity ratio of 0.12. The company has a market cap of $2.43 billion, a PE ratio of -11.69 and a beta of 0.50.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). Geron had a negative return on equity of 73.79% and a negative net margin of 15,990.68%. The firm had revenue of $0.88 million during the quarter, compared to the consensus estimate of $0.34 million. During the same period last year, the company earned ($0.09) earnings per share. The company’s revenue for the quarter was up 2941.4% on a year-over-year basis. As a group, research analysts anticipate that Geron will post -0.34 EPS for the current year.

Institutional Trading of Geron

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Darwin Global Management Ltd. acquired a new position in Geron in the 2nd quarter valued at about $106,185,000. Tokio Marine Asset Management Co. Ltd. acquired a new position in shares of Geron in the first quarter valued at approximately $333,000. Renaissance Technologies LLC purchased a new position in shares of Geron during the second quarter valued at approximately $3,315,000. Price T Rowe Associates Inc. MD boosted its position in Geron by 999.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,064,963 shares of the biopharmaceutical company’s stock worth $6,815,000 after acquiring an additional 1,877,184 shares during the last quarter. Finally, Algert Global LLC purchased a new stake in Geron in the 2nd quarter worth approximately $539,000. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.